VIM and breast cancer: By using a xenograft model in nude mice (MDA-MB-231) (60 mg/kg, by the intravenous route, for 4 weeks), the authors showed MHP-1 treatment led to inhibition of breast cancer metastasis, followed by a decreased expression of TGFβ type I receptor kinase (ALK5) and vimentin and increased expression of E-cadherin by MHP-1 [57].